Functional imaging of cognitive impairment in Parkinson's disease

Clinical EEG and Neuroscience

Volumn 41, Issue 3, 2010, Pages 119-126

  Fitzpatrick, T ^a   Mattis, P ^a,b   Eideiberg, David ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Brain metabolism; Brain networks; Cerebral blood flow; Cognition; Imaging; Parkinson's disease; Positron emission tomography; Treatment response

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TRACER; RADIOPHARMACEUTICAL AGENT;

BEHAVIOR DISORDER; BRAIN METABOLISM; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; HUMAN; IN VIVO STUDY; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROIMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL (TOPIC); COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC USE; PATHOPHYSIOLOGY; PROCEDURES; SCINTISCANNING;

AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77955610820     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005941004100303     Document Type: Review

References (88)

1. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707. (Pubitemid 47597592)
2. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-874. (Pubitemid 29495548)
3. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, de Pedro J. The clinical impression of severity index for Parkinson's disease: International validation study. Mov Disord 2009; 24: 211-217.
4. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-1263. (Pubitemid 41645899)
5. Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, et al. Cognitive impairments in advanced PD without dementia. Neurology 2002; 59: 1320-1324. (Pubitemid 35285980)
6. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130: 1834-1846. (Pubitemid 47343798)
7. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-560. (Pubitemid 38295472)
8. Mentis MJ, Mcintosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, Edwards C, Mattis P, Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002; 159: 746-754. (Pubitemid 34465047)
9. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004; 22: 236-245. (Pubitemid 38891002)
10. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007; 34: 714-723. (Pubitemid 44827754)
11. Bosboom JL, Stoffers D, Wolters E. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004; 111: 1303-1315. (Pubitemid 39468392)
12. Argyelan M, Carbon M, Ghilardi MF, Feigin A, Mattis P, Tang C, Dhawan V, Eidelberg D. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci 2008; 28: 10687-10695.
13. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722. (Pubitemid 43754399)
14. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-1748. (Pubitemid 37521630)
15. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 2003; 106: 83-88. (Pubitemid 36806171)
16. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
17. Weiner MF, Hynan LS, Parikh B, Zaki N, White CL III, Bigio EH, et al. Can Alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J Geriatr Psychiatry Neurol 2003; 16: 245-250.
18. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819. (Pubitemid 46568532)
19. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer's pathology. Alzheimer's Dis Assoc Disord 2009; 23: 295-297.
20. Goldmann Gross R, Siderowf A, Hurtig HI. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies: a spectrum of disease. Neurosignals 2008; 16: 24-34. (Pubitemid 350308318)
21. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol 2003; 106: 191-201.
22. Dagher A, Owen AM, Boecker H, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 2001; 124: 1020-1032. (Pubitemid 32458514)
23. Marie RM, Lozza C, Chavoix C, Defer GL, Baron JC. Functional imaging of working memory in Parkinson's disease: compensations and deficits. J Neuroimaging 2007; 17: 277-285. (Pubitemid 47481073)
24. Owen AM, Doyon J, Dagher A, Sadikot A, Evans AC. Abnormal basal ganglia outflow in Parkinson's disease identified with PET: implications for higher cortical functions. Brain 1998; 121 ( Pt 5): 949-965. (Pubitemid 28220900)
25. Nakamura T, Ghilardi MF, Mentis M, Dhawan V, Fukuda M, Hacking A, Moeller JR, Ghez C, Eidelberg D. Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease. Hum Brain Mapp 2001; 12: 42-60. (Pubitemid 32048356)
26. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 2003; 16: 193-210. (Pubitemid 37517825)
27. Mentis MJ, Dhawan V, Nakamura T, Ghilardi MF, Feigin A, Edwards C, Ghez C, Eidelberg D. Enhancement of brain activation during trial-and-error sequence learning in early PD. Neurology 2003; 60: 612-619. (Pubitemid 36246078)
28. Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, et al. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 2004; 24: 7-16. (Pubitemid 38021264)
29. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992; 49: 1262-1268.
30. Nagano-Saito A, Kato T, Arahata Y, Washimi Y, Nakamura A, Abe Y, et al. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 2004; 22: 553-561. (Pubitemid 38759417)
31. Thiel A, Hilker R, Kessler J, Habedank B, Herholz K, Heiss WD. Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study. J Neural Transm 2003; 110: 1289-1301. (Pubitemid 37500750)
32. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009; 24: 854-862.
33. Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord 2009; 24: 1504-1511.
34. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009; 32: 548-557.
35. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27: 597-605. (Pubitemid 46310425)
36. Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2005; 2: 361-371.
37. Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D. Network modulation in the treatment of Parkinson's disease. Brain 2006; 129: 2667-2678. (Pubitemid 44522100)
38. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 19559-19564.
39. Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, Ma Y, Eidelberg D. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006; 31: 301-307. (Pubitemid 43728986)
40. Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci 2001; 2: 685-694. (Pubitemid 33674814)
41. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008; 70: 1470-1477. (Pubitemid 351521942)
42. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343-1349. (Pubitemid 44613283)
43. Monchi O, Ko JH, Strafella AP. Striatal dopamine release during performance of executive functions: a [(11)C] raclopride PET study. Neuroimage 2006; 33: 907-912.
44. Vemaleken I, Buchholz HG, Kumakura Y, Siessmeier T, Stoeter P, Bartenstein P, et al. 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp 2007; 28: 931-939.
45. Carbon M, Marié RM. Functional imaging of cognition in Parkinson's disease. Curr Opin Neurol 2003; 16: 475-480. (Pubitemid 36951824)
46. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 1358-1365. (Pubitemid 34587144)
47. Cheesman AL, Barker FiA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1204-1210.
48. Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with (11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008; 163: 171-182.
49. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fuorodopa positron emission tomographic study. Arch Neurol 2000; 57: 470-475. (Pubitemid 30212118)
50. van Beilen M, Portman AT, Kiers HA, Maguire RP, Kaasinen V, Koning M, et al. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat Disord 2008; 14: 224-228.
51. Bruck A, Aalto S, Nurmi E, Bergman J, Rinne JO. Cortical 6-(18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 2005; 26: 891-898. (Pubitemid 40249492)
52. Au WL, Adams JR, Troiano AR, Stoessl AJ. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 2005; 134: 24-33. (Pubitemid 40403637)
53. Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 2004; 21: 1497-1507. (Pubitemid 38446574)
54. Carbon M, Eidelberg D. Functional imaging of sequence learning in Parkinson's disease. J Neurol Sci 2006; 248: 72-77. (Pubitemid 44647286)
55. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253: 242-247. (Pubitemid 43255898)
56. Janson AM, Fuxe K, Sundstrom E, Agnati LF, Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6- tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988; 132: 589-591.
57. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998; 71: 2439-2446. (Pubitemid 28531254)
58. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002; 23: 581-594. (Pubitemid 36527678)
59. Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003; 984: 224-232.
60. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 2006; 188: 509-520. (Pubitemid 46758966)
61. Ellis JR, Villemagne VL, Nathan PJ, Mulligan RS, Gong SJ, Chan JG, et al. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem 2008; 90: 404-412.
62. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Langstrom B, Nordberg A. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Bert) 2007; 191: 1005-1014. (Pubitemid 46399149)
63. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 2008; 29: 1204-1217. (Pubitemid 351822413)
64. Ellis JR, Nathan PJ, Villemagne VL, Mulligan RS, Saunder T, Young K, et al. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-(18F]fluoro-A-85380 PET. Psychopharmacology (Berl) 2009; 202: 79-91.
65. Schmaljohann J, Gundisch D, Minnerop M, Bucerius J, Joe A, Reinhardt M, et al. In vitro evaluation of nicotinic acetylcholine receptors with 2-(18F]F-A85380 in Parkinson's disease. Nucl Med Biol 2006; 33: 305-309.
66. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009; 66: 866-877.
67. Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008; 43: 430-439.
68. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319. (Pubitemid 38269583)
69. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Bnen J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931-1934. (Pubitemid 44967366)
70. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB-PET. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
71. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008; 39: 1027-1033.
72. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-910.
73. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology; 74: 77-84.
74. Brooks DJ. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 2009; 24 (suppl 2): S742-747.
75. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365-10371.
76. Jahanshahi M, Wilkinson L, Gahir H, Dharminda A, Lagnado DA. Medication impairs probabilistic classification learning in Parkinson's disease. Neuropsychologia; 48: 1096-1103.
77. Funkiewiez A, Ardouin C, Cools R, Krack P, Fraix V, Batir A, et al. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease. Mov Disord 2006; 21: 1656-1662. (Pubitemid 44742194)
78. Feigin A, Ghilardi MF, Carbon M, Edwards C, Fukuda M, Dhawan V, Margouleff C, Ghez C, Eidelberg D. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 2003; 60: 1744-1749. (Pubitemid 36737067)
79. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125: 584-594. (Pubitemid 34194413)
80. Carbon M, Ghilardi MF, Feigin A, Fukuda M, Silvestri G, Mentis MJ, Ghez C, Moeller JR, Eidelberg D. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp 2003; 19: 197-211. (Pubitemid 36736662)
81. Schroeder U, Kuehler A, Haslinger B, Erhard P, Fogel W, Tronnier VM, et al. Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study. Brain 2002; 125: 1995-2004.
82. Campbell MC, Karimi M, Weaver PM, Wu J, Perantie DC, Golchin NA, et al. Neural correlates of STN DBS-induced cognitive variability in Parkinson disease. Neuropsychologia 2008; 46: 3162-3169.
83. Alessandro S, Ceravolo R, Brusa L, Pierantozzi M, Costa A, Galati S, et al. Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. J Neurol Sci; 289: 44-48.
84. Lee PH, Yong SW, An YS. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after Cholinesterase inhibitor therapy. J Nucl Med 2008; 49: 2006-2011.
85. Kalbe E, Voges J, Weber T, Haarer M, Baudrexel S, Klein JC, et al. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 2009; 72: 42-49.
86. Venneri A. Imaging treatment effects in Alzheimer's disease. Magn Reson Imaging 2007; 25: 953-968. (Pubitemid 47081351)
87. Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, Moeller JR, Eidelberg D. Metabolic conelates of levodopa response in Parkinson's disease. Neurology 2001; 57: 2083-2088. (Pubitemid 33126878)
88. Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, Carbon M, Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 2008; 28: 4201-4209.